VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors.

ABSTRACT: The inadequate transport of drugs into the tumor tissue caused by its abnormal vasculature is a major obstacle to the treatment of cancer. Anti-vascular endothelial growth factor (anti-VEGF) drugs can cause phenotypic alteration and maturation of the tumor's vasculature. However, whether this consistently improves delivery and subsequent response to therapy is still controversial. Clinical results indicate that not all patients benefit from antiangiogenic treatment, necessitating the development of criteria to predict the effect of these agents in individual tumors. We demonstrate that, in anti-VEGF-refractory murine tumors, vascular changes after VEGF ablation result in reduced delivery leading to therapeutic failure. In these tumors, the impaired response after anti-VEGF treatment is dir

SUBMITTER: Rohrig F 

PROVIDER: S-EPMC5237662 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature